Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigations on the Efficacy of Ketamine in Depression in Comparison to Electroconvulsive Therapy
Brief Summary: While there are effective treatments for depression available, some patients do not see results with these options. Often, these patients are referred to electroconvulsive therapy (ECT) which has drawbacks such as adverse side effects, cost, and limited access. Recent research shows that intravenous ketamine may be an alternative option for these patients due to its rapid antidepressant effect sustained with multiple treatments.

This study will recruit 240 participants from the ECT waiting list at the five participating hospitals, and randomize them to either the ketamine or ECT treatment arm. Participants in the ketamine treatment arm will receive 0.5mg/kg ketamine intravenously (IV) over 40 minutes as described in the study schedule. Participants in the ECT treatment arm will receive ECT as described in the study schedule and as decided by their treating physician. Throughout the study, clinical, neuroimaging, molecular, and cognitive assessments will be conducted.

The aim of this study is to show that compared to ECT, ketamine treatment produces faster results, has less side effects, requires less or shorter hospitalizations, and is less expensive. The measures collected throughout the study (clinician scales, self-reports, blood samples, and neuroimaging) may help with predicting if future patients will respond to ECT or ketamine. This could lead to faster, more effective treatment for patient with depression.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): GLYX-13, 1 mg/kg, GLYX-13, 10 mg/kg, GLYX-13, 5 mg/kg, Normal Saline
C: Arm Label: Placebo then MK-0657; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Arm Label: MK-0657 then Placebo; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Intervention Type: DRUG; Name: MK-0657; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657
D: Arm Label: Intravenous Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Intravenous Ketamine | Arm Label: Electroconvulsive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Electroconvulsive Therapy | Intervention Type: DRUG; Name: Intravenous Ketamine; Assigned to Arm(s): Intravenous Ketamine | Intervention Type: PROCEDURE; Name: Electroconvulsive Therapy; Assigned to Arm(s): Electroconvulsive Therapy

Answer: D